Through a directed share issue, Vicore raised roughly SEK 336 million to pursue a phase III trial in Covid-19 patients. Despite the mathematical dilution effect, we reiterate our Base case of SEK 62 per share – reflecting our belief that Vicore will leverage these cash to create long-term value. We also give a brief comment on the Gilead/Galapagos Phase III Discontinuation in IPF.